Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403984 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1403845 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3207354 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404048 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL30980916 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404082 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404107 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL11859421 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404023 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9158672 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| CN-116332818-B | Tetrahydropyrrole derivatives and their use | 王喆明 | 2023-12-15 | — | — | CN | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116332917-A | Pyridine cyanoguanidine derivative and application thereof | 王喆明 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332818-A | Tetrahydropyrrole derivatives and their use | 王喆明 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-107083352-A | Produce the recombinant cell of 2 hydroxy-iso-butyric acids | 赢创罗姆有限公司 | 2017-08-22 | — | — | CN | disclosed |
| WO-2017032699-A1 | METHOD FOR PRODUCING LOW-BOILING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2017-03-02 | — | — | WO | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | HRH3 606/4885MAPT 3643/4885CYP1A2 2737/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885MAPT 4029/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.